- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02253277
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (CoRNea)
A Phase Ib Single-arm, Open-label, Multicenter Study to Assess the Safety and Tolerability of Combined Treatment With Nilotinib 300mg BID and Ruxolitinib Increasing Dose in CML and Ph+ ALL Patients
연구 개요
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Berlin, 독일, 13353
- Novartis Investigative Site
-
Frankfurt, 독일, 60590
- Novartis Investigative Site
-
Jena, 독일, 07740
- Novartis Investigative Site
-
Leipzig, 독일, 04103
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Patients of the first stratum must have chronic myeloid leukemia receiving nilotinib first-line therapy or receiving second-line or subsequent-line treatment with nilotinib.
Patients of the second stratum must have CML in AP/BC or relapsed/refractory Ph+ ALL, or be Ph+ ALL patients with MRD with or without prior nilotinib pretreatment;
Patients must have adequate end organ function, as defined by:
- Creatinine < 2.0 x upper limit of normal (ULN)
- Total bilirubin < 1.5 x ULN (< 3.0 x ULN if related to disease or polymorphism, such as Mb. Gilbert)
- ALT and AST < 2.5 x ULN (< 5.0 x ULN if related to disease)
- Serum lipase ≤ 1.5 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN (< 5.0 x ULN if related to disease);
Patients must have the following electrolyte values within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication:
- Potassium
- Magnesium
- Phosphate
- Total calcium (corrected for serum albumin);
Female patients of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days before initiation of study drug. All WOCBP must use highly effective contraceptive methods throughout and during 3 months after study;
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 for patients in CP, ≤ 2 for patients in AP/BC or with relapsed/refractory Ph+ ALL or with Ph+ ALL with MRD;
Patient has the following laboratory values within 7 days of starting study drug:
- For CML and Ph+ ALL patients: platelet count > 75 x 109/L and ANC > 1.0 x 109/L
Exclusion Criteria:
Patient must not have evidence of active malignancy other than the existing CML or ALL
Patient must not receive drugs that interfere with coagulation or inhibits platelet function, with the exception of aspirin ≤ 150 mg per day or low molecular weight heparin.
Patient must not have history of platelet dysfunction, bleeding diathesis, and/or coagulopathy in the 6 months prior to screening;
Patient must not require treatment with any strong CYP3A4 inducer or inhibitor
Patient must not have history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes and their excipients;
Patients must not take other investigational drugs within 28 days prior to screening;
Patient must not be pregnant or lactating at screening and/or baseline;
Patient must not have impaired cardiac functions
Other protocol-defined inclusion/exclusion criteria may apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Nilotinib and Ruxolitinib
The study included two strata, which were to be treated in parallel.
The first stratum consisted of CML-patients in CP, which had been on nilotinib treatment before entering the study.
These patients did not optimally respond to the previous treatment.
The second stratum consisted of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment.
Patients were treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib.
The dose expansion phase (12 months) began following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID.
In this phase, safety and tolerability of the MTD and/or potential RPIID was to be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.
|
Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules.
Nilotinib was not dosed by weight or body surface area.
Medication labels were in German and complied with the legal requirements of Germany.
They included storage conditions for the drug but no information about the patient.
The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets.
Medication labels were in German and complied with the legal requirements of Germany.
They included storage conditions for the drug but no information about the patient.
The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Occurrence of dose limiting toxicities (DLTs)
기간: Baseline, up to day 28 (equals first cycle)
|
Occurrence of DLTs during cycle 1
|
Baseline, up to day 28 (equals first cycle)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Safety and tolerability profile of nilotinib and ruxolitinib administered in combination
기간: Baseline, up to month 12
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RPIID) of ruxolitinib in combination with nilotinib.
(timeframe, baseline up to month 12)
|
Baseline, up to month 12
|
Trough levels of nilotinib and ruxolitinib administered in combination
기간: Baseline, up to month 12
|
Trough levels will be determined by measuring the minimum plasma concentration (Cmin).
|
Baseline, up to month 12
|
Clinical activity of nilotinib and ruxolitinib administered in combination
기간: Baseline and at 3, 6, and 12 months
|
Chronic myeloid leukemia in chronic phase: assessment of molecular response: MMR (≤0.1% BCR-ABL) and MR4 (≤0.001%
BCR-ABL) at 3, 6, 12 months; Advanced disease: assessment of cytogenetic response will be based on evaluating percentage of Ph+ metaphases
|
Baseline and at 3, 6, and 12 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Andreas Hochhaus, Prof. Dr. med., Universitätsklinikum Jena
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- CAMN107YDE19
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
만성 골수성 백혈병에 대한 임상 시험
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
Nilotinib에 대한 임상 시험
-
Baylor College of Medicine모병만성 골수성 백혈병 | 만성 골수성 백혈병, BCR/ABL 양성, 관해 상태 | 차도의 만성 골수성 백혈병미국
-
Asan Medical Center빼는
-
Hospices Civils de Lyon완전한
-
Hospices Civils de LyonNovartis알려지지 않은
-
Medical College of WisconsinMemorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University of Chicago; Emory University 그리고 다른 협력자들완전한
-
University of JenaNovartis Pharmaceuticals; Ludwig-Maximilians - University of Munich모집하지 않고 적극적으로